The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Capricor Therapeutics Inc. following allegations that the company may have issued materially misleading business information. The investigation stems from a July 27, 2026 Reuters article reporting that FDA staff reviewers raised concerns about the effectiveness data for Capricor's cell therapy deramiocel, causing shares to fall 64% that day. The Rosen Law Firm is preparing a class action seeking recovery of investor losses on a contingency fee basis. Investors who purchased Capricor securities are encouraged to contact the firm for information about joining the prospective class action.
Capricor Therapeutics IncFDA staff concerns about effectiveness data for deramiocel and potential securities claims.